CA2280181A1 - Activite anti-angiogenique amelioree des derives constamment charges d'hormones steroidiennes - Google Patents

Activite anti-angiogenique amelioree des derives constamment charges d'hormones steroidiennes Download PDF

Info

Publication number
CA2280181A1
CA2280181A1 CA002280181A CA2280181A CA2280181A1 CA 2280181 A1 CA2280181 A1 CA 2280181A1 CA 002280181 A CA002280181 A CA 002280181A CA 2280181 A CA2280181 A CA 2280181A CA 2280181 A1 CA2280181 A1 CA 2280181A1
Authority
CA
Canada
Prior art keywords
group
carbon atoms
alkyl
radical selected
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002280181A
Other languages
English (en)
Inventor
Anat Biegon
Marcus E. Brewster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmos Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL12018497A external-priority patent/IL120184A/xx
Priority claimed from US08/833,074 external-priority patent/US6083990A/en
Application filed by Individual filed Critical Individual
Publication of CA2280181A1 publication Critical patent/CA2280181A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'agonistes ou d'antagonistes constamment chargés de stéroïdes comme compositions puissamment anti-angiogéniques, qui renferment comme principe actif un composé de formules générales I (médicament), II (anti-oestrogènes) ou III, dans lesquelles "médicament" est un agoniste ou un antagoniste des stéroïdes, un mélange agoniste-antagoniste ou un agoniste partiel, et les substituants sont tels que définis dans la spécification.
CA002280181A 1997-02-09 1998-02-04 Activite anti-angiogenique amelioree des derives constamment charges d'hormones steroidiennes Abandoned CA2280181A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IL12018497A IL120184A (en) 1997-02-09 1997-02-09 Pharmaceutical compositions comprising permanently charged derivatives of steroid agonists or antagonists for preventing angiogenesis
IL120184 1997-02-09
US08/833,074 US6083990A (en) 1997-04-02 1997-04-02 Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
US08/833,074 1997-04-02
PCT/US1998/002176 WO1998034583A2 (fr) 1997-02-09 1998-02-04 Activite anti-angiogenique amelioree des derives constamment charges d'hormones steroidiennes

Publications (1)

Publication Number Publication Date
CA2280181A1 true CA2280181A1 (fr) 1998-08-13

Family

ID=26323367

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002280181A Abandoned CA2280181A1 (fr) 1997-02-09 1998-02-04 Activite anti-angiogenique amelioree des derives constamment charges d'hormones steroidiennes

Country Status (5)

Country Link
EP (1) EP0981337A4 (fr)
JP (1) JP2001511182A (fr)
AU (1) AU746007B2 (fr)
CA (1) CA2280181A1 (fr)
WO (1) WO1998034583A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3046792B1 (fr) * 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3484463B1 (fr) * 2016-08-19 2020-02-12 The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology Transfer Modulateurs sélectifs du récepteur des oestrogènes (serms) conférant une protection contre la dégénérescence des photorécepteurs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914561A (en) * 1957-08-06 1959-11-24 Wm S Merrell Co Amine derivatives of triphenylethylene
US2971001A (en) * 1959-10-21 1961-02-07 Wm S Merrell Co Quaternary salts of triphenylethanols, -ethylenes, and -ethanes
BE637389A (fr) * 1962-09-13
EP0776661A1 (fr) * 1992-10-27 1997-06-04 Nippon Kayaku Kabushiki Kaisha Préparation combiné d'un antiestrogène et d'un glucocorticoide pour le traitement des desordres autoimmunitaires
US5650425A (en) * 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists

Also Published As

Publication number Publication date
EP0981337A4 (fr) 2003-03-12
JP2001511182A (ja) 2001-08-07
AU6056298A (en) 1998-08-26
AU746007B2 (en) 2002-04-11
WO1998034583A2 (fr) 1998-08-13
EP0981337A2 (fr) 2000-03-01
WO1998034583A3 (fr) 1998-11-05

Similar Documents

Publication Publication Date Title
US5650425A (en) Permanently ionic derivatives of steroid hormones and their antagonists
EP0954299B1 (fr) Analogues de thyroxine depourvus d'activite hormonale pour le traitement de tumeurs malignes
US8367644B2 (en) Methods and compounds useful to induce apoptosis in cancer cells
US6169104B1 (en) Di-aryl ethers and their derivatives as anti-cancer agents
US6433012B1 (en) Method for inhibiting inflammatory disease
EP1024800B1 (fr) Analogues de la thyroxine ne possedant pas d'activite hormonale significative destines au traitement des tumeurs malignes
EP3638233B1 (fr) Tinostamustine destinée à être utilisée dans le traitement du cancer de l'ovaire
US6150407A (en) Methods for inhibiting angiogenesis
WO1998014181A1 (fr) Traitement et prevention des affections hepatiques
WO1997046228A9 (fr) Procede de traitement de tumeurs malignes avec des analogues de thyroxine n'ayant pas d'activite hormonale importante
US6083990A (en) Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
AU731125B2 (en) Method for inducing death of neoplastic cells using piperazine oxirane derivatives
AU746007B2 (en) Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
EP1877061B1 (fr) Methode et composition permettant d'inhiber la proliferation cellulaire et l'angiogenese
US7056908B2 (en) Pharmaceutical compositions and methods for preventing skin tumor formation and causing regression of existing tumors
US20230210859A1 (en) Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
Brewster et al. Evaluation of the anticancer action of a permanently charged tamoxifen derivative, tamoxifen methiodide: an MRI study
KR100484014B1 (ko) 호르몬활성을가지지않는티록신유사체로악성종양을치료하는방법
CN102006866A (zh) 激酶蛋白结合抑制剂
EP0897720A1 (fr) Utilisation de droloxifene pour la prévention du cancer du sein

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20070205